Therapixel announces launch of prospective study on the utility of Artificial Intelligence (AI) as part of second reading breast cancer screening mammograms
The first French prospective clinical study to evaluate the…
Therapixel releases a new version of MammoScreen® that leverages prior exams for better accuracy
For the first time, an AI-based decision support software…
Therapixel announces close of 15 M€ series B financing to deploy MammoScreen® 2D/3D
The Company will accelerate the commercial deployment of…
Therapixel receives FDA clearance for use of its AI-based breast cancer screening software MammoScreen® on Digital Breast Tomosynthesis
AI-powered reading aid for screening 2D & 3D mammography…
Therapixel receives FDA 510(k) clearance for MammoScreen™
AI-powered reading aid for screening mammography improves…